Cited by 133Attention Deficit Hyperactivity DisorderBipolar Disorder and TreatmentSchizophrenia research and treatment

The Canadian Network for Mood and Anxiety Treatments (Canmat) Task Force Recommendations for the Management of Patients with Mood Disorders and Comorbid Attention-Deficit/Hyperactivity Disorder

Bond, David J., Hadjipavlou, George, Lam, Raymond W., McIntyre, Roger S., Beaulieu, Serge, Schaffer, Ayal, Weiss, Margaret·2012·Annals of Clinical Psychiatry

Abstract

Background: Patients with bipolar disorder (BD) and major depressive disorder (MDD) experience adult attention-deficit/hyperactivity disorder (ADHD) at rates substantially greater than the general population. Nonetheless, ADHD frequently goes untreated in this population. Methods: We reviewed the literature regarding the management of adult ADHD in patients with mood disorders. Because a limited number of studies have been conducted in adults, our treatment recommendations also are partly informed by research in children and adolescents with BD+ADHD or MDD+ADHD, adults with ADHD, and our clinical experience. Results: In individuals with mood disorders, ADHD is best diagnosed when typical symptoms persist during periods of sustained euthymia. Individuals with BD+ADHD, particularly those with bipolar I disorder (BD I), are at risk for mood destabilization with many ADHD treatments, and should be prescribed mood-stabilizing medications before initiating ADHD therapies. Bupropion is a reasonable first-line treatment for BD+ADHD, while mixed amphetamine salts and methylphenidate also may be considered in patients determined to be at low risk for manic switch. Modafinil and cognitive-behavioral therapy (CBT) are second-line choices. In patients with MDD+ADHD and moderate to severe depression, MDD should be the treatment priority, whereas in mildly depressed or euthymic patients the order may be reversed. First-line treatments for MDD+ADHD include bupropion, an antidepressant plus a long-acting stimulant, or an antidepressant plus CBT. Desipramine, nortriptyline, and venlafaxine are second-line options. Conclusions: Clinicians should be vigilant in screening for comorbid ADHD in mood disorder patients. ADHD symptoms can respond to appropriately chosen treatments.

Integrity signals

Registry

Crossref · 10.1177/104012371202400104

Cites

171 of 171 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Cites

Flagged first, then by citations

1 of the 172 references couldn’t be matched to a known paper.

Cited by

Sorted by citations

Authors
Bond, D. J., Hadjipavlou, G., Lam, R. W., McIntyre, R. S., Beaulieu, S., Schaffer, A., & Weiss, M.
Affiliations
  • University of British Columbia (CA)
  • University Health Network (CA)
  • Douglas Mental Health University Institute (CA)
  • Sunnybrook Health Science Centre (CA)
  • Children's & Women's Health Centre of British Columbia (CA)
Corresponding author
Bond, David J.
Venue
Annals of Clinical Psychiatry
Published
2012-02
Volume
24
Issue
1
Pages
23-37
ISSN
  • 1040-1237 (ISSN-L)
  • 1547-3325
OpenAlex
W48669398
Cited by
133
References
172
Citations by year
2026: 4 · 2025: 6 · 2024: 8 · 2023: 7 · 2022: 5 · 2021: 9 · 2020: 8 · 2019: 13 · 2018: 7 · 2017: 10 · 2016: 16 · 2015: 8 · 2014: 13 · 2013: 12 · 2012: 7
FWCI
9.11
Type
journal article
Language
en
Open access
closed
Locations
  • Annals of Clinical Psychiatry (publishedVersion)
  • PubMed (publishedVersion)
  • PubMed
Funders
Canadian Institutes of Health Research
Topics
  • Health Sciences › Medicine › Psychiatry and Mental health › Attention Deficit Hyperactivity Disorder
  • Health Sciences › Medicine › Psychiatry and Mental health › Bipolar Disorder and Treatment
  • Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
Keywords
attention deficit hyperactivity disorder, comorbidities, bipolar disorder, major depressive disorder, mood disorders, ADHD treatment, bupropion, mixed amphetamine salts, methylphenidate, modafinil, cognitive behavioral therapy, mood stabilizers, manic switch, ADHD screening, treatment guidelines
MeSH terms
Adult, Central Nervous System Stimulants, Antidepressive Agents, Attention Deficit Disorder with Hyperactivity, Bipolar Disorder, Canada, Major Depressive Disorder, Humans, Comorbidity, Cognitive Behavioral Therapy, Lithium Compounds, Mood Disorders, Advisory Committees

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review